Is there a need for new therapies for rheumatoid arthritis?

Journal of Rheumatology

Volumn 32, Issue SUPPL. 73, 2005, Pages 3-7

  Fleischmann, Roy M ^a,b  

^a UNIVERSITY OF TEXAS SOUTHWESTERN MEDICAL CENTER   (United States)

^b UNIVERSITY OF TEXAS SOUTHWESTERN MEDICAL CENTER   (United States)

Author keywords

Adverse effects; antirheumatic agents; Biological response modifiers; Disease modifying antirheumatic drugs; Rheumatoid arthritis; Treatment efficacy

Indexed keywords

ADALIMUMAB; ANALGESIC AGENT; ANTIMALARIAL AGENT; ANTIRHEUMATIC AGENT; AZATHIOPRINE; BIOLOGICAL RESPONSE MODIFIER; CERTOLIZUMAB PEGOL; CYCLOSPORIN; CYTOKINE RECEPTOR ANTAGONIST; CYTOTOXIC T LYMPHOCYTE ANTIGEN 4; ETANERCEPT; GOLD; HYDROXYCHLOROQUINE; INFLIXIMAB; INTERLEUKIN 4; LEFLUNOMIDE; METHOTREXATE; NONSTEROID ANTIINFLAMMATORY AGENT; PENICILLAMINE; RECOMBINANT INTERLEUKIN 1 RECEPTOR BLOCKING AGENT; RITUXIMAB; SALAZOSULFAPYRIDINE; STEROID; TUMOR NECROSIS FACTOR RECEPTOR ANTAGONIST; UNCLASSIFIED DRUG;

ADOPTIVE IMMUNOTHERAPY; B LYMPHOCYTE; BLOOD TOXICITY; CANCER; CONFERENCE PAPER; CONGESTIVE HEART FAILURE; DEMYELINATING DISEASE; DISEASE COURSE; DRUG EFFECT; DRUG EFFICACY; EYE TOXICITY; GASTROINTESTINAL TOXICITY; HUMAN; INFECTION; INJECTION SITE REACTION; LIVER TOXICITY; LUNG TOXICITY; LYMPHOMA; MALAISE; NEPHROTOXICITY; PANCREAS DISEASE; PRIORITY JOURNAL; RHEUMATOID ARTHRITIS; SEPSIS; SIDE EFFECT; SKIN TOXICITY; SYSTEMIC LUPUS ERYTHEMATOSUS; TREATMENT OUTCOME; TUBERCULOSIS; DRUG COMBINATION; IMMUNOLOGY; REVIEW; RHEUMATOLOGY;

ANTIRHEUMATIC AGENTS; ARTHRITIS, RHEUMATOID; B-LYMPHOCYTES; BIOLOGICAL RESPONSE MODIFIERS; DRUG THERAPY, COMBINATION; HUMANS; RHEUMATOLOGY; TREATMENT OUTCOME;

EID: 13444260904     PISSN: 0315162X     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Conference Paper

References (19)

1. O'Dell JR, Leff R, Paulsen G, et al. Treatment of rheumatoid arthritis with methotrexate and hydroxychloroquine, methotrexate and sulfasalazine, or a combination of the three medications: results of a two-year, randomized, double-blind, placebo-controlled trial. Arthritis Rheum 2002;46:1164-70.
2. Klareskog L, van der Heijde D, de Jager JP, et al. Therapeutic effect of the combination of etanercept and methotrexate, compared with each treatment alone in patients with rheumatoid arthritis: a double-blind randomised controlled trial. Lancet 2004;363:675-81.
3. Boers M, Verhoeven AC, Markusse HM, et al. Randomised comparison of combined step-down prednisolone, methotrexate and sulphasalazine with sulphasalazine alone in early rheumatoid arthritis. Lancet 1997;350:309-18.
4. Smolen JS, Kalden JR, Scott DL, et al. Efficacy and safety of leflunomide compared with placebo and sulphasalazine in active rheumatoid arthritis: a double-blind, randomised, multicentre trial. European Leflunomide Study Group. Lancet 1999;353:259-66.
5. Strand V, Cohen S, Schiff M, et al. Treatment of active rheumatoid arthritis with leflunomide compared with placebo and methotrexate. Leflunomide Rheumatoid Arthritis Investigators Group. Arch Intern Med 1999;159:2542-50.
6. Tugwell P, Pincus T, Yocum D, et al. Combination therapy with cyclosporine and methotrexate in severe rheumatoid arthritis. The Methotrexate-Cyclosporine Combination Study Group. N Engl J Med 1995;333:137-41.
7. Furst DE, Lindsley H, Baethge B. et al. Dose-loading with hydroxychloroquine improves the rate of response in early, active rheumatoid arthritis: a randomized, double-blind six-week trial with eighteen-week extension. Arthritis Rheum 1999;42:357-65.
8. Kremer JM, Genovese MC, Cannon GW, et al. Concomitant leflunomide therapy in patients with active rheumatoid arthritis despite stable doses of methotrexate. A randomized, double-blind, placebo-controlled trial. Ann Intern Med 2002;137:726-33.
9. Paget SK. Rheumatoid arthritis. In: Klippel JH, Weyand CM, Wortmann R, editors. Primer on the rheumatic diseases. 11th Ed. Atlanta, GA: The Arthritis Foundation; 1997:168.
10. Galindo-Rodriguez G, AviÒa-Zubieta JA, Russell AS, Suarez-Almazor ME. Disappointing long-term results with disease modifying antirheumatic drugs. A practice based study. J Rheumatol 1999;26:2337-43.
11. Bathon JM, Martin RW, Fleischmann RM, et al. A comparison of etanercept and methotrexate in patients with early rheumatoid arthritis. N Engl J Med 2000;343:1586-93.
12. Cohen S, Hurd E, Cush J, et al. Treatment of rheumatoid arthritis with anakinra, a recombinant human interleukin-1 receptor antagonist, in combination with methotrexate: results of a twenty-four week, multicenter, randomized, double-blind, placebo-controlled trial. Arthritis Rheum 2002;46:614-24.
13. Klareskog L, Wajdula J, Pedersen R. A long-term, open-label trial of the safety and efficacy of etanercept (25 mg twice weekly) in patients with rheumatoid arthritis (interim analysis of 4-year data) [abstract]. Ann Rheum Dis 2003;61:189.
14. Lipsky PE, van der Heijde DM, St. Clair EW, et al. Infliximab and methotrexate in the treatment of rheumatoid arthritis. Anti-Tumor Necrosis Factor Trial in Rheumatoid Arthritis with Concomitant Therapy Study Group. N Engl J Med 2000;343:1594-602.
15. Moreland LW, Baumgartner SW, Schiff MH, et al. Treatment of rheumatoid arthritis with a recombinant human tumor necrosis factor receptor (p75)-Fc fusion protein. N Engl J Med 1997;337:141-7.
16. Smolen JS, Emery P, Bathon J, et al. Treatment of early rheumatoid arthritis with infliximab plus methotrexate or methotrexate alone: preliminary results of the ASPIRE trial [abstract]. Ann Rheum Dis 2003;62 Suppl 9:OP0001.
17. van de Putte LBA, Atkins C, Malaise M, et al. Adalimumab (D2E7) monotherapy in the treatment of patients with severely active rheumatoid arthritis [abstract]. Ann Rheum 2002;46 Suppl 9:467.
18. Weinblatt ME, Keystone EC, Furst DE, et al. Adalimumab, a fully human anti-tumor necrosis factor alpha monoclonal antibody, for the treatment of rheumatoid arthritis in patients taking concomitant methotrexate: the ARMADA trial. Arthritis Rheum 2003;48:35-45.
19. Moreland LW, Schiff MH, Baumgartner SW, et al. Etanercept therapy in rheumatoid arthritis. A randomized controlled trial. Ann Intern Med 1999;130:478-86.